CACC insider files Form 144 to sell 20,000 founder shares via Goldman Sachs
Rhea-AI Filing Summary
Form 144 notice shows a proposed sale of 20,000 shares of common stock through Goldman Sachs & Co. LLC with an aggregate market value of $9,857,400. The shares represent founder stock acquired on 07/19/1972 and are split into two entries of 10,000 shares each, both described as issued for services rendered. The filing lists 11,237,661 shares outstanding, and the approximate sale date is 10/09/2025. The filer certifies they are not aware of undisclosed material adverse information and indicates no sales of these securities in the past three months.
Positive
- Sale size is small relative to outstanding shares: 20,000 of 11,237,661 (~0.18%)
- Brokered through a major dealer: transaction routed via Goldman Sachs & Co. LLC
- Securities were long-held founder shares acquired on 07/19/1972, indicating no recent insider grants
Negative
- Insider intends to sell founder shares, which may be viewed negatively by some investors despite small size
- Form does not confirm execution; approximate sale date is 10/09/2025, so actual disposition is pending
Insights
Insider proposes a small founder-stock sale scheduled for 10/09/2025.
The filing documents a proposed sale of 20,000 founder shares via Goldman Sachs with an aggregate market value of $9,857,400. These shares were acquired on 07/19/1972 as compensation for services, and the filing reports 11,237,661 shares outstanding.
As written, the sale equals about 0.18% of outstanding stock (20,000/11,237,661). The primary risk is straightforward: this is a notice of intent to sell and does not confirm execution. Watch the 10/09/2025 approximate sale date for actual transaction filings that would show completed dispositions.
Filing uses standard Rule 144 disclosures and includes the required signer representation.
The filer affirms no undisclosed material adverse information and notes no related sales in the prior three months. The two equal founder-share entries indicate the shares originated from the issuer as compensation.
Key dependencies are the timing and whether a trading plan exists; the form references Rule 10b5-1 compliance language but does not provide plan dates. Investors should monitor subsequent Form 4 or Form 144 amendments around 10/09/2025 for execution details within days after the approximate sale date.